PTD-DBM: Hair Growth Peptide That Outperformed Minoxidil in Study

In 2017, a research team at Yonsei University published a study in the Journal of Investigative Dermatology showing that a synthetic peptide called PTD-DBM outperformed minoxidil in stimulating hair regrowth in mice. The finding drew significant attention in the hair loss research community because PTD-DBM works through a fundamentally different mechanism than any existing approved treatment — by directly activating the Wnt signaling pathway inside dermal papilla cells.

What Is PTD-DBM?

PTD-DBM is a chimeric peptide composed of two functional domains. The first is a protein transduction domain (PTD) — a short, positively charged sequence that enables the peptide to cross cell membranes. The second is a DBM sequence derived from Dishevelled-binding motif, which allows the peptide to bind and inhibit CXXC5, a scaffold protein that acts as a negative regulator of the Wnt/beta-catenin pathway.

In plain terms: CXXC5 normally puts the brakes on Wnt signaling in hair follicle cells. PTD-DBM releases those brakes, allowing Wnt/beta-catenin to push follicles from resting (telogen) into growth phase (anagen).

The 2017 Study Results

Choi et al. applied PTD-DBM topically to shaved mouse skin and compared results to minoxidil (5%), vehicle control, and valproic acid (a known Wnt activator). At 28 days, PTD-DBM produced greater hair coverage, increased follicle density, and accelerated anagen entry compared to all other groups. Histological analysis confirmed more follicles in anagen phase in PTD-DBM-treated skin.

The researchers also applied PTD-DBM to human skin explants and observed increased expression of beta-catenin target genes — a meaningful signal that the mechanism translates at least partially to human tissue.

Why Minoxidil Works Differently

Minoxidil opens ATP-sensitive potassium channels, which increases scalp blood flow and may indirectly promote follicle survival. It does not directly activate follicle cycling machinery. Its efficacy in androgenetic alopecia is real but modest, and it requires indefinite daily use. Stopping minoxidil typically results in reversal of any gains within months.

PTD-DBM's mechanism is upstream — it targets the transcriptional machinery that governs whether a follicle grows or rests. This makes it conceptually more powerful and potentially longer-lasting, though no human longevity data exist yet.

Current Research Status

As of 2026, PTD-DBM remains a research peptide. No human clinical trials have been published. It is not FDA-approved for any indication. The compound is available from research chemical suppliers, but quality control is variable and there is no standardized formulation for human use.

Some compounding pharmacies have included PTD-DBM in scalp serums, often at concentrations of 0.1–0.5% in a hydrogel or aqueous base. The Yonsei team used a hydrogel formulation in their mouse study, applying 1 mg/mL concentration.

How PTD-DBM Compares to GHK-Cu

GHK-Cu (copper tripeptide-1) also activates Wnt signaling but through an indirect, upstream mechanism involving stem cell activation and growth factor upregulation. PTD-DBM is more direct — it specifically blocks the inhibitor of Wnt. In theory, combining both could produce additive effects, though no combination study has been conducted.

Dosing and Application

No validated human dosing protocol exists. Based on the mouse study, topical application of a 1 mg/mL solution once daily is the closest reference point. Users experimenting with PTD-DBM typically apply a small amount (0.5–1 mL) to affected areas of the scalp once daily, massaging gently. The peptide should be applied to clean, dry scalp, not washed off.

FAQ

Is PTD-DBM safe for humans? No significant safety signals have emerged in animal studies, and the topical route limits systemic exposure. However, human safety data are extremely limited. It should be treated as an investigational compound.

Can I buy PTD-DBM legally? In the US, it can be purchased from research chemical vendors as a research compound. It is not legal to sell for human consumption, and the quality of available products varies widely.

Will PTD-DBM work for androgenetic alopecia specifically? The mouse model used bald spots induced by depilation, not androgen-driven follicle miniaturization. Whether PTD-DBM addresses the DHT-mediated follicle shrinkage in AGA is unknown. It likely needs to be combined with an anti-androgen (finasteride, dutasteride, topical spironolactone) for AGA cases.

Related Articles

• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It
• Best Peptide Stacks for Recovery, Fat Loss, and Longevity

Track your supplements in Optimize.